Skip to content
1910 logo

1910

1910 is a YC Winter 2019 (W19) company. Based in Boston, MA, USA. Team of 20.

  • AI-powered Drug Discovery

About 1910

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

1910 builds an AI-native drug discovery platform that combines multimodal biological data, large AI models, and high-throughput lab automation to identify both small and large molecule therapeutics. The platform, called ITO, targets the earliest and most failure-prone stages of drug discovery, replacing conventional experimental screening cycles with computationally guided candidate selection. Pharmaceutical and biotech partners use it to accelerate the path from target to viable therapeutic candidate.

Go-to-market

Pharma and biotech companies engage 1910 through a partnering model, contacting the team directly to explore collaboration on specific drug discovery programs.

From the Y Combinator listing

How 1910 describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

Multimodal AI Platform for Modality Agnostic Drug Discovery™

We are the only AI-native biotech pioneering small and large molecule therapeutics discovery by integrating massive multimodal data, frontier AI models, and high-throughput lab automation into an infrastructure for AI-enabled drug discovery.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
Boston, MA, USA
Team size
20
Status
Active
Stage
Growth

Founders (1)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works